Martin Citron

Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation

Anne-Laure Mahul-Mellier, Melek Firat Altay, Niran Maharjan, Nadine Ait‐Bouziad et autres

Alpha-synuclein (aSyn) post-translational modifications (PTM), especially phosphorylation at serine 129 and C-terminal truncations, are highly enriched in Lewy bodies (LB), Lewy neurites, and other pathological aggregates in Parkinson's disease and synucleinopathies. However, the precise role of these PTM in pathology formation, neurodegeneration, …

ch, us, gb, se, cn, be, qa (code pays fourni par la source)

A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

Jonathan Behr, Ryan Birol, Cornelis Blauwendraat, Bradford H. Casey et autres

Identifying effective therapeutic targets for Parkinson's disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson's Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. …

us, gb, be (code pays fourni par la source)

Dissecting the differential role of C-terminal truncations in the regulation of aSyn pathology formation and the biogenesis of Lewy bodies

Anne-Laure Mahul-Mellier, Melek Firat Altay, Niran Maharjan, Nadine Ait‐Bouziad et autres

Abstract Alpha-synuclein (aSyn) post-translational modifications (PTMs), particularly phosphorylation at serine 129 and C-terminal truncations, are highly enriched in Lewy bodies (LBs), Lewy neurites, and other types of aSyn pathological aggregates in the brain of patients with Parkinson’s disease (PD) and other synucleinopathies. …

fr, ch, gb, se, be (code pays fourni par la source)

Spatial recovery of the murine gut microbiota after antibiotics perturbation

Mariia Taguer, Jiang Xiao, Ross Crawford, Shi H et autres

ABSTRACT Bacterial communities are highly complex, with interaction networks dictating ecosystem function. Bacterial interactions are constrained by the spatial organization of these microbial communities, yet studying the spatial organization of microbial communities at the single-cell level has been technically challenging. Here, we …

us (code pays fourni par la source)

Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

Diana L. Price, Asma Khan, Rachel C. Angers, Alvaro De Pablo Cardenas et autres

Since first linked to genetic forms of Parkinson’s disease (PD) 1 , our collective understanding of the role of alpha-synuclein (ASYN) in normal physiological processes and disease has substantially expanded. However, significant gaps in our understanding of ASYN and its contribution to …

be (code pays fourni par la source)

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

Diana L. Price, Asma Khan, Rachel C. Angers, Alvaro De Pablo Cardenas et autres

Direct targeting of alpha-synuclein (ASYN) has emerged as a disease-modifying strategy for Parkinson's disease and other synucleinopathies which is being approached using both small molecule compounds and ASYN-targeted biologics. Minzasolmin (UCB0599) is an orally bioavailable and brain-penetrant small molecule ASYN misfolding inhibitor …

be (code pays fourni par la source)

Preclinical In Vivo Characterization of UCB0599, an Orally Available, Small Molecule Inhibitor of α-Synuclein Misfolding in Development for Parkinson’s Disease (S36.007)

Diana L. Price, Asma Khan, Rachel C. Angers, Alvaro De Pablo Cardenas et autres

To evaluate the preclinical effects of chronic dosing of the clinical-stage small molecule α-synuclein misfolding inhibitor UCB0599 in α-synuclein transgenic mice.

us (code pays fourni par la source)

Current directions in tau research: Highlights from Tau 2020

Claire E. Sexton, Heather M. Snyder, Dirk Beher, Adam L. Boxer et autres

Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 …

us, ch, be, fr, gb (code pays fourni par la source)

Monitoring of a progressive functional dopaminergic deficit in the A53T-AAV synuclein rats by combining 6-[18F]fluoro-L-m-tyrosine imaging and motor performances analysis

Guillaume Becker, Anne Michel, Mohamed Ali Bahri, Georges Mairet‐Coello et autres

be, fr, gb (code pays fourni par la source)

Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody

Marie Albert, Georges Mairet‐Coello, Clément Danis, Sarah Lieger et autres

Tauopathies are neurodegenerative diseases characterized by the intraneuronal accumulation of aggregated tau. The staging of this neurodegenerative process is well established for Alzheimer's disease as well as for other tauopathies. The stereotypical pattern of tau pathology in these diseases is consistent with …

fr, be (code pays fourni par la source)

The making of a Lewy body: the role of alpha-synuclein post-fibrillization modifications in regulating the formation and the maturation of pathological inclusions.

Anne‐Laure Mahul‐Mellier, Johannes Burtscher, Niran Maharjan, Nadine Ait‐Bouziad et autres

Although converging evidence point to alpha-synuclein (a-syn) aggregation and Lewy body (LB) formation as central events in Parkinson's disease (PD), the molecular mechanisms that regulate these processes and their role in disease pathogenesis remain poorly understood. Herein, we applied an integrative biochemical, …

ch, gb, se, cn, be (code pays fourni par la source)

Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau

Jean‐Philippe Courade, Rachel C. Angers, Georges Mairet‐Coello, Nathalie Pacico et autres

In Alzheimer's disease (AD) and other tauopathies, the cytosolic protein Tau misfolds and forms intracellular aggregates which accumulate within the brain leading to neurodegeneration. Clinical progression is tightly linked to the progressive spread of Tau pathology throughout the brain, and several lines …

be, gb (code pays fourni par la source)